novorapid flexpen injection 100 uml
novo nordisk pharma (singapore) pte ltd - insulin aspart - injection - 100 u/ml - insulin aspart 100 u/ml
novorapid penfill injection 100 uml
novo nordisk pharma (singapore) pte ltd - insulin aspart - injection - 100 u/ml - insulin aspart 100 u/ml
ryzodeg flextouch solution for injection
novo nordisk a/s - insulin degludec (70%), insulin aspart (30%) - solution for injection - 100u/ml
novorapid flexpen solution for s/c or i/v injection
novo nordisk a/s - insulin aspart - solution for s/c or i/v injection - 100u/ml
novorapid penfill solution for s/c or i/v injection
novo nordisk a/s - insulin aspart - solution for s/c or i/v injection - 100u/ml
levemir flexpen solution for injection
novo nordisk a/s - insulin detemir (recombinant) - solution for injection - 100u/ml
levemir penfill solution for injection
novo nordisk a/s - insulin detemir (recombinant) - solution for injection - 100u/ml
novorapid flexpen solution for s/c or i/v injection
novo nordisk a/s - insulin aspart - solution for s/c or i/v injection - 100u/ml
mytolac
boucher & muir (new zealand) limited t/a bnm group - lanreotide acetate 27.3%{relative} equivalent to lanreotide 120 mg - solution for injection - 120 mg - active: lanreotide acetate 27.3%{relative} equivalent to lanreotide 120 mg excipient: acetic acid water for injection - indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. - the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. - the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
mytolac
boucher & muir (new zealand) limited t/a bnm group - lanreotide acetate 27.3%{relative} equivalent to lanreotide 60mg - solution for injection - 60 mg - active: lanreotide acetate 27.3%{relative} equivalent to lanreotide 60mg excipient: acetic acid water for injection - indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. - the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. - the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.